Where will this drug
go next?
Most drug investing is anchored on the lead indication. The asymmetric returns come when a molecule expands — like GLP-1s going from diabetes to obesity to cardiovascular.
biotechTV uses peer-drug evidence — same mechanism, other diseases — to surface where each pipeline asset could expand next. Two-minute, vertical-video explainers grounded in cosine-similar MoAs from the connection-mapper graph.
Biology you can hold in your head.
Every deck opens with a primer that uses an analogy first — receptors as doorbells, gene therapy as rewriting source code — before introducing jargon. The visuals come from a custom prompt pipeline that generates editorial-style biology illustrations.
Receptors, pathways, and the actual chemistry that moves a stock.
Each deck includes a labeled mechanism diagram — the receptor activation, downstream effectors, and clinical readout — so the thesis is anchored on biology, not vibes.
From lead indication to multi-billion-dollar adjacency.
Alrizomadlin (AAPG) could expand into treating Chronic Lymphocytic Leukemia (CLL), leveraging similar MoA successes.
ALN-5288 (ALNY) could expand into Parkinson's Disease, Tauopathies, and ALS based on peer MoA successes.
ARO-DIMER-PA (ARWR) could expand into treating Dyslipidemia and HoFH based on similar MoA peers.
Every thesis is grounded in peer drugs already proving the same MoA in other indications. No vibes — just cosine-similar mechanisms hitting different diseases.
Drug names always carry their parent ticker — Tirzepatide (LLY), Ozempic (NVO), DB-OTO (REGN) — so you instantly know who owns the upside.
Hook → primer → mechanism → peer evidence → hypothesis → real-world burden → takeaways. Designed to brief you on a name in the time it takes to refill coffee.